Mesenchymal Stem Cell Transplantation for Ischemic Diseases: Mechanisms and Challenges

Nguyen, Thi-Tuong Van; Vu, Ngoc Bich; Pham, Phuc Van

doi:10.1007/s13770-021-00334-3

Cited by 26 publications

(16 citation statements)

References 199 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, research into the cellular transport behaviors of hard-to-transfect cells is critical, in order to design delivery technologies tailored for these cells based on a detailed understanding of the special delivery problem. In the present work, we perform an investigation on cellular transport of exogenous entities in a type of hard-to-transfect cells, namely, bone marrow-derived mesenchymal stem cells (BMSCs), which are widely used in tissue engineering and regenerative medicine. − …”

mentioning

confidence: 99%

Probing the Intracellular Delivery of Nanoparticles into Hard-to-Transfect Cells

et al. 2022

View full text Add to dashboard Cite

Hard-to-transfect cells are cells that are known to present special difficulties in intracellular delivery of exogenous entities. However, the special transport behaviors underlying the special delivery problem in these cells have so far not been examined carefully. Here, we combine single-particle motion analysis, cell biology studies, and mathematical modeling to investigate nanoparticle transport in bone marrow-derived mesenchymal stem cells (BMSCs), a technologically important type of hard-to-transfect cells. Tat peptide-conjugated quantum dots (QDs-Tat) were used as the model nanoparticles. Two different yet complementary single-particle methods, namely, pair-correlation function and single-particle tracking, were conducted on the same cell samples and on the same viewing stage of a confocal microscope. Our results reveal significant differences in each individual step of transport of QDs-Tat in BMSCs vs a commonly used model cell line, HeLa cells. Single-particle motion analysis demonstrates that vesicle escape and cytoplasmic diffusion are dramatically more difficult in BMSCs than in HeLa cells. Cell biology studies show that BMSCs use different biological pathways for the cellular uptake, vesicular transport, and exocytosis of QDs-Tat than HeLa cells. A reaction−diffusion−advection model is employed to mathematically integrate the individual steps of cellular transport and can be used to predict and design nanoparticle delivery in BMSCs. This work provides dissective, quantitative, and mechanistic understandings of nanoparticle transport in BMSCs. The investigative methods described in this work can help to guide the tailored design of nanoparticle-based delivery in specific types and subtypes of hard-to-transfect cells.

show abstract

mentioning

confidence: 99%

Probing the Intracellular Delivery of Nanoparticles into Hard-to-Transfect Cells

et al. 2022

View full text Add to dashboard Cite

show abstract

“…So far, MSCs have been successfully isolated from a variety of tissues including dental pulp [ 2 ], periodontal ligament [ 3 ], adipose [ 4 ], synovial fluid [ 5 ], umbilical cord [ 6 ], and amniotic fluid [ 7 ]. MSCs have the ability to differentiate into osteoblasts [ 8 ], chondrocytes [ 9 ], adipocytes [ 10 ], vascular endothelial cells [ 11 ], cardiomyocytes [ 12 ], and neuronal cells [ 13 ]. Due to multidirectional differentiation potential, MSCs-based therapy seems superior in disease treatment.…”

Section: Mesenchymal Stem Cells and Extracellular Vesiclesmentioning

confidence: 99%

Mesenchymal Stem Cell-Derived Apoptotic Bodies: Biological Functions and Therapeutic Potential

Tang

Luo

Zhang

et al. 2022

Cells

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are non-hematopoietic progenitor cells with self-renewal ability and multipotency of osteogenic, chondrogenic, and adipogenic differentiation. MSCs have appeared as a promising approach for tissue regeneration and immune therapies, which are attributable not only to their differentiation into the desired cells but also to their paracrine secretion. MSC-sourced secretome consists of soluble components including growth factors, chemokines, cytokines, and encapsulated extracellular vesicles (EVs). Apoptotic bodies (ABs) are large EVs (diameter 500𠀓2000 nm) harboring a variety of cellular components including microRNA, mRNA, DNA, protein, and lipids related to the characteristics of the originating cell, which are generated during apoptosis. The released ABs as well as the genetic information they carry are engulfed by target cells such as macrophages, dendritic cells, epithelial cells, and fibroblasts, and subsequently internalized and degraded in the lysosomes, suggesting their ability to facilitate intercellular communication. In this review, we discuss the current understanding of the biological functions and therapeutic potential of MSC-derived ABs, including immunomodulation, tissue regeneration, regulation of inflammatory response, and drug delivery system.

show abstract

“…Mesenchymal stem cells (MSCs) have been recognized as major therapeutics and widely applied in regenerative medicine [ 1 ]. Preclinical and clinical studies of MSCs exhibit their therapeutic effects in a broad field of disorders and injuries including wound healing [ 2 ], immune and ischemia diseases [ 3 , 4 ], soft tissue defects, hair loss [ 5 ] and covid-19 [ 6 ]. Various types of MSCs derived from different resources such as umbilical cord-derived MSCs(UC-MSCs) [ 7 ], adipocyte-derived MSCs(Ad-MSCs) [ 8 ] and bone marrow-derived MSCs(BM-MSCs) [ 9 ] have been applied in the treatment of a variety of refractory diseases, including tissue damage and immune diseases.…”

Section: Introductionmentioning

confidence: 99%

Comparison of CD146 +/− mesenchymal stem cells in improving premature ovarian failure

et al. 2022

View full text Add to dashboard Cite

Background Mesenchymal stem cells (MSCs) are a heterogeneous group of subpopulations with differentially expressed surface markers. CD146 + MSCs correlate with high therapeutic and secretory potency. However, their therapeutic efficacy and mechanisms in premature ovarian failure (POF) have not been explored. Methods The umbilical cord (UC)-derived CD146 +/− MSCs were sorted using magnetic beads. The proliferation of MSCs was assayed by dye670 staining and flow cytometry. A mouse POF model was established by injection of cyclophosphamide and busulfan, followed by treatment with CD146 +/− MSCs. The therapeutic effect of CD146 +/− MSCs was evaluated based on body weight, hormone levels, follicle count and reproductive ability. Differential gene expression was identified by mRNA sequencing and validated by RT-PCR. The lymphocyte percentage was detected by flow cytometry. Results CD146 +/− MSCs had similar morphology and surface marker expression. However, CD146 + MSCs exhibited a significantly stronger proliferation ability. Gene profiles revealed that CD146 + MSCs had a lower levels of immunoregulatory factor expression. CD146 + MSCs exhibited a stronger ability to inhibit T cell proliferation. CD146 +/− MSCs treatment markedly restored FSH and E2 hormone secretion level, reduced follicular atresia, and increased sinus follicle numbers in a mouse POF model. The recovery function of CD146 + MSCs in a reproductive assay was slightly improved than that of CD146 - MSCs. Ovary mRNA sequencing data indicated that UC-MSCs therapy improved ovarian endocrine locally, which was through PPAR and cholesterol metabolism pathways. The percentages of CD3, CD4, and CD8 lymphocytes were significantly reduced in the POF group compared to the control group. CD146 + MSCs treatment significantly reversed the changes in lymphocyte percentages. Meanwhile, CD146 - MSCs could not improve the decrease in CD4/8 ratio induced by chemotherapy. Conclusion UC-MSCs therapy improved premature ovarian failure significantly. CD146 +/− MSCs both had similar therapeutic effects in repairing reproductive ability. CD146 + MSCs had advantages in modulating immunology and cell proliferation characteristics.

show abstract

Mesenchymal Stem Cell Transplantation for Ischemic Diseases: Mechanisms and Challenges

Cited by 26 publications

References 199 publications

Probing the Intracellular Delivery of Nanoparticles into Hard-to-Transfect Cells

Probing the Intracellular Delivery of Nanoparticles into Hard-to-Transfect Cells

Mesenchymal Stem Cell-Derived Apoptotic Bodies: Biological Functions and Therapeutic Potential

Comparison of CD146 +/− mesenchymal stem cells in improving premature ovarian failure

Contact Info

Product

Resources

About